Marilena Cesari, MD

IRCCS Istituto Ortopedico Rizzoli
Bologna, Emilia-Romagna, Italy

Disclosure information not submitted.

Presentation(s):

• RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL

  Wednesday, November 13, 2024
  1:00 PM – 2:45 PM PST

• Paper 19 - IS THERE A ROLE FOR MIFAMURTIDE IN NONMETASTATIC EXTREMITY HIGH-GRADE OSTEOSARCOMA PATIENTS? RESULTS OF PROSPECTIVE ITALIAN SARCOMA GROUP (ISG/OS-2) AND SPANISH SARCOMA GROUP (GEIS-33) TRIALS

  Thursday, November 14, 2024
  1:45 PM – 3:15 PM PST